Top Injectable Manufacturer in Venezuela – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 20 hours ago
- 9 min read
Last Updated: July 24, 2026
TL;DR: Venezuela is a market of roughly 28 to 29 million residents — after an emigration of some 7.7 million people — where a prolonged humanitarian and economic crisis has hollowed out both public procurement and domestic manufacturing, leaving deep, genuine demand for affordable sterile injectables. Local production fell by around 70% over the crisis and the industry now depends on imports for roughly 98% of its inputs; medicine shortages reached about 85% at the 2018 peak, malaria resurged to some 101,924 cases in 2024, and a 2024 national hospital survey found around 74% of basic supplies missing. Market access runs through the Instituto Nacional de Higiene “Rafael Rangel” (INHRR) under the Ministry of Health, whose Registro Sanitario is filed on the SIVERC platform by a Venezuela-licensed sponsoring pharmacist and is valid for five years. Because both Venezuela and India are parties to the Hague Apostille Convention, the Certificate of Pharmaceutical Product and GMP certificate are apostilled rather than consular-legalised — but the real barrier is payment: US sanctions carve out medicine, yet correspondent-banking and foreign-exchange friction make private settlement hard, which is why PAHO’s Strategic Fund is the cleanest compliant channel. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to over 30 countries, and supports Venezuelan partners with INHRR dossiers, apostilled documentation, Spanish artwork and Zone IVb stability packages.
Key Takeaways
Regulatory pathway, precisely: the marketing authorisation is the Registro Sanitario, evaluated by the Instituto Nacional de Higiene “Rafael Rangel” (INHRR) and its Junta Revisora de Productos Farmacéuticos under the Ministry of Health, filed through the online SIVERC system by a Venezuela-licensed Farmacéutico Patrocinante. The registration is valid for five years, renewable, with renewal filed six months before expiry; INHRR uses its own national dossier structure rather than a formally mandated CTD.
Documentation runs on apostille, not consular legalisation. Venezuela has been a party to the Hague Apostille Convention since 1999 and India since 2005, so the Certificate of Pharmaceutical Product and GMP certificate can be apostilled directly by each country’s competent authority — though strained diplomatic and document-flow conditions can still create practical delays.
Payment is the real constraint, not the product. US sanctions explicitly carve out medicine and medical supplies (General License 4C), so supplying injectables is lawful, but correspondent-banking de-risking and foreign-exchange controls make private USD settlement difficult. The PAHO Strategic Fund — the pooled regional procurement mechanism that has supplied Venezuela with antiretrovirals, anti-TB drugs and antimalarials — is the most compliant, bankable route.
You cannot register or import directly, and Spanish is required. A foreign manufacturer must appoint a Venezuela-established local representative and work through an authorised importer or droguería; the dossier and all labelling are in Spanish. Stability is ICH Climatic Zone IVb (30°C/75% RH), a natural fit for an Indian manufacturer that already tests to that condition.
Introduction: Why an Injectable Manufacturer in Venezuela Must Meet Global Standards
Venezuela’s health system serves roughly 28 to 29 million residents through a public network of hospitals and ambulatory centres, the social-security institute’s pharmacies (the IVSS high-cost pharmacies that dispense oncology, immunosuppressant and chronic-disease medicines) and a private sector that now carries much of the burden of supply. Years of economic contraction have degraded public procurement: a 2024 national hospital survey documented around 74% of basic supplies missing, oxygen lacking in some 85% of hospitals and local anaesthesia unavailable in about half, while the social-security high-cost pharmacies report recurrent stock-outs measured in months. In that environment the medicines that do reach patients arrive through a mix of channels — pooled international procurement led by PAHO, humanitarian programmes under the UN response plan, the residual public system, and private pharmacies where high out-of-pocket cost falls on patients. For a sterile injectable supplier, the practical reality is that the compliant, bankable doors are the PAHO Strategic Fund and a properly registered private importer, rather than a functioning centralised government tender.
The demand behind that dependence is severe and well documented. Medicine shortages reached roughly 85% at the 2018 peak of the crisis; malaria, which had been near elimination, resurged to become one of the region’s largest burdens and still recorded some 101,924 cases in 2024; and the collapse of routine services drove the re-emergence of diphtheria and measles — Venezuela accounted for the majority of measles cases in the Americas in 2018 — alongside sharp rises in maternal and infant mortality. Interruptions to antiretroviral supply reached 100% in early 2018, affecting more than 80,000 people living with HIV, and the degradation of hospital care has left anaesthesia, antibiotics, oncology and critical-care injectables in chronically short supply. Across all of it, the injectable essentials have to arrive sterile, correctly documented and exactly to specification, batch after batch. Venezuela needs reliable imported sterile injectables from manufacturers whose quality systems will survive scrutiny — and whose pricing works within humanitarian and pooled-procurement budgets.
What Sets a World-Class Injectable Manufacturer in Venezuela Apart
The first differentiator is genuine sterile-manufacturing capability rather than a general plant with a filling line bolted on. Sterile injectables bypass every natural barrier the body has, so sterility assurance cannot be inferred from a finished-product test alone — it has to be designed into the facility. Farbe Firma’s operation in Gujarat, India is built around ISO Class 5 aseptic filling zones within classified surrounding areas, unidirectional personnel and material flows, validated terminal sterilisation or aseptic processing according to the molecule, routine media-fill validation, environmental and personnel monitoring with trended data, and Water-for-Injection generation and distribution held under continuous control. That architecture is what turns a certificate of analysis into a defensible claim — and, because both INHRR registration and PAHO Strategic Fund supply rest on documented WHO-GMP quality, it is precisely the evidence a Venezuelan submission is built to present.
The second differentiator is market-access support built around Venezuela’s actual pathway, including the parts that are inconvenient. The marketing authorisation is the Registro Sanitario, evaluated by INHRR and its Junta Revisora de Productos Farmacéuticos and filed through the SIVERC platform by a Venezuela-licensed sponsoring pharmacist; the registration is valid for five years and INHRR works to its own national dossier structure rather than a formally mandated CTD, with review timelines that have historically run long. Because both Venezuela and India are parties to the Hague Apostille Convention, the Certificate of Pharmaceutical Product and GMP certificate are apostilled directly rather than consular-legalised. A manufacturer in Gujarat cannot register or import in its own name — it must appoint a Venezuela-established local representative and work through an authorised importer or droguería — and it must be candid about the payment channel: US sanctions carve out medicine under General License 4C, so the supply is lawful, but correspondent-banking and foreign-exchange friction make private settlement hard, which is why the PAHO Strategic Fund so often provides the cleanest route.
Quality Systems Behind Every Batch We Ship to Venezuela
Every Farbe Firma injectable batch destined for Venezuela is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by HPLC and, where the monograph requires it, GC. Sterility and bacterial endotoxin testing by LAL are performed on every batch, with container-closure integrity and particulate matter assessed against compendial limits, and water content by Karl Fischer titration where the dosage form demands it. Methods are validated to ICH expectations and specifications are set against USP, BP, IP or EP as the market and customer require, with the pharmacopoeial basis stated on the certificate of analysis rather than left implicit — the kind of documented quality that pooled-procurement mechanisms and INHRR review both demand.
Behind release testing sits the quality architecture that makes those results meaningful. Stability programmes run on three batches under real-time conditions per ICH Q1A, with photostability per ICH Q1B where the molecule warrants it; for Venezuela, which sits in ICH Climatic Zone IVb, we hold long-term data at 30°C/75% RH — the demanding hot-and-humid condition suited to a tropical, Caribbean-facing distribution chain. Change control, deviation management, CAPA, supplier qualification and annual product quality review operate as a connected system rather than as separate files, and batch records are retained so that any vial can be reconstructed from raw material to release years later. Dossiers are compiled to the INHRR structure with Spanish artwork and leaflets prepared to the regulator’s requirements, and the site is maintained in a state of continuous inspection readiness — which matters equally to WHO prequalification and to the PAHO Strategic Fund suppliers Venezuela increasingly relies on.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Venezuela for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, oncology support, anaesthesia and analgesia, cardiovascular and critical-care molecules, obstetric medicines, vitamins and parenteral-nutrition adjuncts, delivered as liquid vials, ampoules, lyophilised presentations and small-volume parenterals — the categories Venezuela’s crisis has left most chronically short, from antimalarials and antibiotics to oncology and emergency medicines. For a Venezuelan importer assembling a hospital portfolio, or an organisation supplying through pooled procurement, that breadth means one audited manufacturing partner, one documentation standard and one point of accountability rather than a patchwork of sources with uneven paperwork.
Our CDMO services scale from a single importer’s launch portfolio to full pooled-procurement volumes. Contract and third-party manufacturing runs under the customer’s brand with technology transfer, analytical method transfer, stability commitment and regulatory documentation handled as one package. We prepare the INHRR dossier for the Registro Sanitario, provide the apostilled Certificate of Pharmaceutical Product and GMP certificate, prepare Spanish labelling and inserts, and supply the batch-level certificates of analysis and retention-sample discipline that an importer or a pooled-procurement agency needs in order to defend a product line. Because India and China are already the principal sources of Venezuela’s imported medicines and raw materials, a WHO-GMP manufacturer that exports to more than 30 countries brings documentation of exactly the kind these channels are designed to accept.
Buyers stay with Farbe Firma because we are straightforward about what the Venezuelan route actually involves. Registration and importation must run through a Venezuela-established local representative and an authorised importer or droguería — a manufacturer cannot register in its own name — and INHRR review timelines have historically been long, so realistic planning matters. The single hardest part is not the product but the payment: US sanctions carve out medicine, yet correspondent-banking de-risking and foreign-exchange controls make private commercial settlement difficult, which is why we work readily through the PAHO Strategic Fund and other humanitarian and pooled channels that are built to move compliant, essential medicines. We are equally candid that the domestic industry, though much reduced, still exists and that price controls shape the private market, so a new entrant competes on verifiable quality, documentation and dependable resupply rather than on availability alone. We would rather set out the local-representative requirement, the payment reality and the registration timeline honestly at the first meeting than discover the gap later.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Venezuela?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable products under ISO Class 5 aseptic conditions and exporting to over 30 countries. For Venezuela we prepare the INHRR dossier for the Registro Sanitario, provide an apostilled Certificate of Pharmaceutical Product and GMP certificate, prepare Spanish labelling and package inserts, and hold Zone IVb stability data. Because a foreign manufacturer cannot register or import in its own name, we work alongside a client’s Venezuela-established local representative and authorised importer, and we supply readily through the PAHO Strategic Fund and other pooled or humanitarian channels.
How is an imported injectable registered in Venezuela, and how long is registration valid?
The marketing authorisation is the Registro Sanitario, evaluated by the Instituto Nacional de Higiene “Rafael Rangel” (INHRR) and its Junta Revisora de Productos Farmacéuticos under the Ministry of Health. The application is filed through the online SIVERC platform by a Venezuela-licensed sponsoring pharmacist (Farmacéutico Patrocinante), together with a physical dossier consignment, and must include quality, stability and an apostilled Certificate of Pharmaceutical Product and GMP certificate. INHRR uses its own national dossier structure rather than a formally mandated CTD. The registration is valid for five years and is renewable, with renewal filed about six months before expiry; historically, review timelines have been long, so realistic scheduling matters.
Does Venezuela accept an apostille, or is consular legalisation required?
An apostille is accepted. Venezuela has been a contracting party to the Hague Apostille Convention since 1999, and India since 2005, so the Certificate of Pharmaceutical Product and GMP certificate are apostilled by each country’s competent authority rather than passed through full consular legalisation. This removes a legalisation step in law; in practice, strained diplomatic conditions and document-flow disruptions can still add time, so Farbe Firma plans the apostille chain into the registration timeline from the outset. The dossier and all labelling are prepared in Spanish.
How do sanctions affect supplying injectables to Venezuela?
Medicine is carved out of the US sanctions programme: General License 4C authorises the export and re-export of medicine, medical devices and related items, and the underlying executive orders do not prohibit transactions ordinarily incident to supplying medicine to relieve human suffering. So supplying WHO-GMP injectables is lawful. The practical obstacle is payment rather than the product — correspondent-banking de-risking and foreign-exchange controls make private USD settlement difficult. For that reason the PAHO Strategic Fund, the pooled regional procurement mechanism that has supplied Venezuela with antiretrovirals, anti-TB drugs and antimalarials, is often the cleanest and most bankable channel, and Farbe Firma is set up to supply through it.
How does public procurement for injectables work in Venezuela?
Centralised government procurement has been severely disrupted by the economic crisis, so the functioning, compliant routes are pooled international procurement and the registered private channel. PAHO’s Strategic Fund procures medicines and health technologies for the region — more than US$800 million in 2024 — and has supplied Venezuela with antiretrovirals, anti-TB drugs, antimalarials and diagnostics in coordination with UN partners. The social-security institute’s high-cost pharmacies dispense certain oncology and chronic-disease medicines, subject to recurrent stock-outs, and private pharmacies carry much of the remaining demand at high out-of-pocket cost. A valid Registro Sanitario and a local representative are the practical preconditions for the private route, while pooled procurement runs on WHO-GMP quality and competitive, humanitarian-budget pricing.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments